ALNY
NASDAQ
$272.67
Alnylam Pharmaceuticals Inc (ALNY)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $434.83 (+59.47%)
Market Cap
$37B
PEG Ratio
0.52
Revenue 5Y CAGR
+49.77%
Forward P/E
30.49
Price Chart
Valuation
Market Cap$37B
P/E117.96
Forward P/E30.49
PEG0.52
P/S8.76
P/B35.76
Profitability
Total Revenue (TTM)$3.71B
Gross Profit (TTM)$3.46B
EBITDA$556M
Profit Margin17%
Operating Margin12%
EPS$2.37
Financial Health
Free Cash Flow Yield1.26%
Growth & Risk
Revenue 5Y CAGR+49.77%
Beta (5Y)0.81
Sharpe Ratio-0.37